Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Social phobia (social anxiety disorder) is a highly prevalent and chronic disorder that is associated with significant comorbidity and disability. Despite recent advances in the pharmacotherapy of the disorder, there is a paucity of randomized controlled trials on patients with comorbid disorders and on maintenance treatment. A randomized placebo-controlled, double-blind multi-site trial of moclobemide, a reversible inhibitor of monoamine oxidase A, was undertaken with 390 subjects. After an initial 12 weeks, there was the option of continuing for an additional 6 months of treatment. The primary efficacy parameter chosen was responder status as defined by the Clinical Global Impression scale change item. From week 4 onwards, there was a significantly higher response rate on moclobemide than on placebo. Superiority of medication over placebo was similar in patients with comorbid anxiety disorders (33% of subjects) and without, as well as in patients with different subtypes of social anxiety disorder; indeed, treatment with moclobemide rather than placebo was the strongest predictor of response. Adverse events were similar across treatment groups, and were typically mild and transient. In the extension phase, response rates remained higher in the moclobemide group, and ratings of tolerability were equally high in both groups. Thus, in a large sample of social anxiety disorder patients with and without comorbid anxiety disorders, moclobemide was both effective and well-tolerated in the short as well as long-term. These data confirm and extend previous findings on the value of moclobemide in the treatment of social anxiety disorder, and strengthen the range of therapeutic options for managing this important disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sheehan, D. V., Harnett-Sheehan, K., & Raj, B. A. (1996) · International Clinical Psychopharmacology · doi:10.1097/00004850-199606003-00015 · Cited by 1,440
Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey
Magee, W. J. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830020077009 · Cited by 996
Cognitive Behavioral Group Therapy vs Phenelzine Therapy for Social Phobia: 12-Week Outcome
Heimberg, R. G., Liebowitz, M. R., Hope, D. A., Schneier, F. R., Holt, C. S., Welkowitz, L. A., Juster, H. R., Campeas, R., Bruch, M. A., Cloitre, M., et al. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.12.1133 · Cited by 585
Phenelzine vs Atenolol in Social Phobia: A Placebo-Controlled Comparison
Liebowitz, M. R., Schneier, F., Campeas, R., Hollander, E., Hatterer, J., Fyer, A., Gorman, J., Papp, L., Davies, S., Gully, R., et al. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.49.4.290 · Cited by 444 · cited 1×
“The first medication class to be shown effective in SAD was that of the classical monoamine oxidase inhibitors (MAOIs) (Liebowitz et al., 1988; Versiani et al., 1988; Gelernter et al., 1991; Liebowitz et al., 1992; Heimberg et al., 1998).”
BackgroundCognitive-Behavioral and Pharmacological Treatments of Social Phobia: A Controlled Study
Gelernter, C. S. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810340070009 · Cited by 404 · cited 1×
“The first medication class to be shown effective in SAD was that of the classical monoamine oxidase inhibitors (MAOIs) (Liebowitz et al., 1988; Versiani et al., 1988; Gelernter et al., 1991; Liebowitz et al., 1992; Heimberg et al., 1998).”
Backgroundvan der Linden, G. J., Stein, D. J., & van Balkom, A. J. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200008002-00004 · Cited by 130
Self-citationWalker, J. R., Van Ameringen, M. A., Swinson, R., Bowen, R. C., Chokka, P. R., Goldner, E., Johnston, D. C., Lavallie, Y.-J., Nandy, S., Pecknold, J. C., et al. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00009 · Cited by 84 · cited 1×
“Furthermore, there have been few long-term studies of the SSRIs in this disorder to date (Walker et al., 2000).”
BackgroundStein, D., Stein, M., Goodwin, W., Kumar, R., & Hunter, B. (2001) · Psychopharmacology · doi:10.1007/s002130100880 · Cited by 39 · cited 1×
“However, a recent post-hoc analysis of patients with more generalized and less generalized SAD indicated that the SSRI, paroxetine, was useful in both groups (Stein et al., 2001).”
BackgroundSelf-citation
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Social Anxiety Disorder: (532272011-001)
(2008) · PsycEXTRA Dataset · doi:10.1037/e532272011-001 · Cited by 258
The evidence-based pharmacotherapy of social anxiety disorder
Blanco, C., Bragdon, L. B., Schneier, F. R., & Liebowitz, M. R. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000119 · Cited by 99
Pharmacotherapy for social anxiety disorder (SAnD)
Williams, T., Hattingh, C. J., Kariuki, C. M., Tromp, S. A., van Balkom, A. J., Ipser, J. C., & Stein, D. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001206.pub3 · Cited by 84
Self-citation
Metadata
- Authors
- Stein, D. J., Cameron, A., Amrein, R., & Montgomery, S. A.
- Venue
- International Clinical Psychopharmacology
- Published
- 2002-07
- Volume
- 17
- Issue
- 4
- Pages
- 161-170
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2132709127
- Cited by
- 65
- References
- 8
- FWCI
- 6.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. https://app.cochat.ai/papers/10.1097/00004850-200207000-00002
- The paper
- Stein, D. J., Cameron, A., Amrein, R., & Montgomery, S. A. (2002). Moclobemide is effective and well tolerated in the long-term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200207000-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.